Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene

  • Bea, A.M.
  • Lamiquiz-Moneo, I.
  • Marco-Benedí, V.
  • Mateo-Gallego, R.
  • Pérez-Calahorra, S.
  • Jarauta, E.
  • Martín, C.
  • Cenarro, A.
  • Civeira, F.
Background and aims: The aim of this work was to compared the effect of lipid lowering drugs among familial hypercholesterolemia (FH) subjects with a functional mutation in LDLR (LDLR FH) and FH with the p.(Leu167del) mutation in APOE. Methods: We retrospectively selected all adults with the p.(Leu167del) mutation on lipid-lowering treatment (n = 22) attending the Lipid Unit at the Hospital Miguel Servet. Age and sex matched LDLR FH from the same Unit were randomly selected as a control group (n = 44). Results: The mean percentage reduction in LDLc was significantly higher in the p.(Leu167del) carriers (-52.1%) than in the LDLR FH (-39.7%) (p = 0.040) when on high intensity statins. Similar differences between groups were observed in non-HDLc -49.4% and -36.4%, respectively (p = 0.030). Conclusions: Subjects with p.(Leu167del) mutation have a higher lipid-lowering response to statins with or without ezetimibe than LDLR FH. This supports the use of genetics for a more efficient management of FH.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Effect of bergamot on lipid profile in humans: A systematic review

  • Lamiquiz-Moneo, Itziar
  • Giné-González, Jaume
  • Alisente, Sonsoles
  • Bea, Ana M.
  • Pérez-Calahorra, Sofía
  • Marco-Benedi, Victoria
  • Baila-Rueda, Lucía
  • Jarauta, Estíbaliz
  • Cenarro, Ana
  • Civeira, Fernando
  • Mateo-Gallego, Rocío
Dyslipidemia is a well-established modifiable cardiovascular risk. Although statins can reduce LDLc by 50-60%, less than 20% of patients with high risk of CVD achieve LDL targets. The aim of this systematic review is to evaluate the effect of the nutraceutical, bergamot (Citrus bergamia), on lipid parameters in humans. PubMed, Embase, Cochrane Library, and Google Scholar databases were searched for interventional and observational studies investigating the effect of bergamot on lipid profile in humans. This systematic review retrieved a total of 442 studies of which 12 articles fulfilled the eligibility criteria and were included in the qualitative synthesis. Based on data, 75% of studies showed a significant decrease in total cholesterol, triglycerides and LDLc. The decrease in total cholesterol varied from 12.3% to 31.3%, from 7.6% to 40.8% in LDLc and from 11.5% to 39.5% in triglycerides. Eight trials reported HDLc increase after intervention with bergamot. Overall, a dose-dependent and possible synergistic effect when administering with statins can be deducted from these trials. It is essential to point out that studies had heterogeneous designs and scientific quality of studies was quite limited. Promising findings reveal an alternative therapeutic option in dyslipidemia management with bergamot supplementation, especially in subjects with statins intolerance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer

  • Cedó, Lídia|||0000-0003-4354-3411
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Baila-Rueda, Lucía
  • Santos, David|||0000-0003-1157-4969
  • Grijalva, Victor
  • Martínez Cignoni, Melanie Raquel|||0000-0002-3469-7980
  • Carbó, José María|||0000-0001-8301-5360
  • Metso, Jari
  • López Vilaró, Laura|||0000-0002-5428-8017
  • Zorzano Olarte, Antonio|||0000-0002-1638-0306
  • Valledor, Annabel F.|||0000-0003-4232-2633
  • Cenarro, Ana
  • Jauhiainen, Matti|||0000-0002-3836-3785
  • Lerma Puertas, Enrique|||0000-0001-7908-2747
  • Fogelman, Alan M.
  • Reddy, Srinivasa T.
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
Low levels of high-density lipoprotein cholesterol (HDLc) have been associated with breast cancer risk, but several epidemiologic studies have reported contradictory results with regard to the relationship between apolipoprotein (apo) A-I and breast cancer. We aimed to determine the effects of human apoA-I overexpression and administration of specific apoA-I mimetic peptide (D-4F) on tumour progression by using mammary tumour virus-polyoma middle T-antigen transgenic (PyMT) mice as a model of inherited breast cancer. Expression of human apoA-I in the mice did not affect tumour onset and growth in PyMT transgenic mice, despite an increase in the HDLc level. In contrast, D-4F treatment significantly increased tumour latency and inhibited the development of tumours. The effects of D-4F on tumour development were independent of 27-hydroxycholesterol. However, D-4F treatment reduced the plasma oxidized low-density lipoprotein (oxLDL) levels in mice and prevented oxLDL-mediated proliferative response in human breast adenocarcinoma MCF-7 cells. In conclusion, our study shows that D-4F, but not apoA-I-containing HDL, hinders tumour growth in mice with inherited breast cancer in association with a higher protection against LDL oxidative modification.